Research Article | Open Access
Hongguang Fan, Litao Li, Xiangjian Zhang, Ying Liu, Chenhui Yang, Yi Yang, Jing Yin, "Oxymatrine Downregulates TLR4, TLR2, MyD88, and NF-B and Protects Rat Brains against Focal Ischemia", Mediators of Inflammation, vol. 2009, Article ID 704706, 10 pages, 2009. https://doi.org/10.1155/2009/704706
Oxymatrine Downregulates TLR4, TLR2, MyD88, and NF-B and Protects Rat Brains against Focal Ischemia
Inflammatory damage plays an important role in cerebral ischemic pathogenesis and may represent a target for treatment. Toll-like receptor-4 (TLR4), toll-like receptor-2 (TLR2), myeloid differentiation factor 88 (MyD88), and nuclear factor kappa-B (NF-B) have been linked to inflammatory reactions. Our previous studies have proved that oxymatrine (OMT) protected ischemic brain injury and this effect may be through the decreasing of NF-B expression. However, little is known regarding the mechanism of OMT in the acute phase of ischemic stroke. We therefore investigated the OMT's potential neuroprotective role and the underlying mechanisms. Male, Sprague-Dawley rats were randomly divided into sham, saline and OMT treatment groups. We used a middle cerebral artery occlusion (MCAO) model and administered OMT intraperitoneally immediately after cerebral ischemia and once daily on the following days. At time points after MCAO, brain water content and infarct size were measured. Immunohistochemistry and RT-PCR were used to analyse the expression of TLR4, TLR2, MyD88, and NF-B at gene and protein level in ischemic brain tissue. The result indicated that OMT protected the brain from damage caused by MCAO; this effect may be through downregulation of the TLR4, TLR2, MyD88, and NF-B.
The excessive inflammatory immune reaction often resides in region of necrosis and ischemic tissue after cerebral infarction and leads to inflammatory injury. The relationship between toll-like receptor-4 (TLR4), toll-like receptor-2 (TLR2), and nonbiological inflammatory injury has been proved [1–3]. It is believed that injured tissue and necrotic cells release endogenous activators (adjuvants). These activators can combine with TLR4 in the cell membrane. With the assistance of cluster of differentiation-14 (CD14) and myeloid differentia protein 2 (MD2), they activate nuclear factor kappa-B (NF-κB) and release a series of cytokines to counteract inflammation. Potential ligands also activate TLR2. They can also induce specific immunity to increase the self-protection ability of the organism. An excessive inflammatory reaction can also damage target cells and tissue [4, 5]. Reducing the inflammatory injury is therefore regarded to be one of major ways to treat acute cerebral infarction.
The pathway mediated by TLR4 includes myeloid differentiation protein-88- (MyD88-) dependent and MyD88-independent pathways . Through TLR4 intrinsic activator, the former can combine with CD14 and anchor on cell surface. Through the effect of MD2, the combination of intrinsic activator and TLR4 can induce a series of intracellular signal transductions. NF-κB is activated to cause release of inflammatory factors. The MyD88-independent pathway belongs to the TLR4-TRIF (TIR-domain-containing adaptor protein inducing IFN) pathway [7, 8] and also has a close relationship with TLR4. The pathway induced by TLR2 is restricted to MyD88-dependent pathways.
Oxymatrine (OMT) has a tetracyclic quinolizine structure. Its molecular formula is O. The structure of OMT is shown in Figure 1. It is an alkaloid extracted from Sophora flavescens Ait (a traditional Chinese medicine (TCM) belonging to the pulse family). The antiinflammatory, antioxidative and antivirus effects of OMT, as well as its role in immunological regulation, have been reported [9, 10]. In recent years, OMT studies have focused mainly on its therapeutic effect against hepatitis and certain types of tumor. There have been few reports on the influence of OMT on cerebrovascular disease.
2. Materials and Methods
OMT was purchased from Shanxi Huike Botanical Development Company Limited (Shanxi, China). It had a purity of 98%. The fine powder of OMT was prepared as a suspension (40 mg/mL) with distilled water and stored at C.
Animal resource and model building. Male Sprague-Dawley (SD) rats (240–260 g) were provided by the Experimental Animal Center, Preclinical Medical College, Hebei Medical University (Hebei, China). They were housed in multilayer laminar flow racks. They could move about freely and had a standard diet and purified water. The room temperature was maintained at 20–2C. According to the methods reported by Longa  and Laing et al. , an animal model of middle cerebral artery occlusion (MCAO) was established by the suture embolic method.
2.1. Experimental Design
To observe the influence of OMT on infarction size, water content, and infiltration of inflammatory cells gene expression and protein expression of TLR4, TLR2, MyD88, and NF-κB in ischemic brain tissue, rats were divided into three groups, that is, OMT treatment group (120 mg/kg), saline group, and sham operation group. Each group was divided into three subgroups at different time points (6 hours, 24 hours, and 48 hours after operation). OMT suspension (40 mg/mL) was given to rats in the OMT treatment group via intraperitoneal injection (120 mg/kg) after MCAO, then once a day. Rats in the saline group received 1 mL of saline replacing OMT after MCAO using the same method.
2.2. Detection of Water Content in Brain Tissue
The water content of brain tissue was detected using the dry-wet weight technique. Five rats of each group were killed, brain tissues were harvested quickly, and the frontal pole (thickness, 4 mm) removed. Brain tissue behind the frontal pole (thickness, 2 mm) was selected for detection of water content. After ascertaining the wet weight (WW) with an electronic balance, brain tissue was put into an oven at constant temperature (100 ± 5°C) for 24 hours. The dry weight (DW) was then obtained. Water content was calculated based on the formula: (WW − DW)/WW × 100%.
2.3. Determination of Infarction Size
2, 3, 5-triphenyltetrazolium (TTC) stain of brain tissue was used. Three rats of each group were killed, brain tissues were harvested quickly, and the frontal pole and cerebella removed. Coronal slices of thickness 2 mm were prepared. Brain tissue was divided into five portions, immersed in 2% TTC phosphonic buffer, and incubated at C for 30 minutes. Viable brain tissue was stained red by TTC, whereas necrotic brain tissue was pale white. Slices were preserved in 10% formaldehyde. The apical side of each slice was imaged. The area of infarction on both sides of each slice was determined by an image analyzer.
2.4. Detection of Expression of TLR4, TLR2, MyD88, and NF-κB in Brain Tissue by Immunohistochemistry
Sections were deparaffinized by a standard method. They were then incubated in 3% /methanol to eliminate endogenous peroxidase activity. After rinsed with phosphate-buffered saline (PBS; 0.01 M, pH 7.4) for antigen retrieval, sections were placed in citrate buffer (0.01 mol/L, pH 6.0) for 30 minutes. Sections were cooled at room temperature and incubated with normal goat serum. Sections were incubated successively with primary antibody (for TLR4 and NF-κB, 1 : 400, Santa Cruz Biotechnology; for TLR2, 1 : 400, LifeSpan Bioscience; for MyD88, 1:100, Santa Cruz Biotechnology) overnight at C. They were rinsed with PBS and incubated with biotinylation secondary antibody fluid at C for 45 minutes. They were rinsed again with PBS and incubated with horseradish peroxidase-labeled streptoavidin at C. Slices were developed with diaminobenzidene (DAB) and counterstained with hematoxylin. They were dehydrated and mounted. The expression of TLR4, TLR2, MyD88, and NF-κB in brain tissue was calculated. Three sections of each brain were selected every 100 m interval. Six scopes were selected randomly in the infarcted cortex and immunopositive cells were counted. The average number was calculated and represented the immunopositive cells of that rat, and three rats were used in each group.
2.5. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Ischemic brain tissue was harvested quickly. Total RNA was extracted with Trizol (Invitrogen) and the density and purity detected. RNA (2 g) of each sample was used for synthesizing cDNA through inverse transcription; 1 L of cDNA was used to carry out PCR amplification. Primers were synthesized by Shanghai Sangon Biological Engineering Technology Company Limited. Correctness of the gene order was proved in GenBank (Table 1). PCR conditions were initial denaturation for 2 minutes at C, 35 cycles of amplification with denaturation at C for 30 seconds, annealing at C for 30 seconds, and extension at C for 40 seconds. After 35 cycles, extension at C for 5 minutes was done. RT-PCR products (5 L) were analyzed by 2% agarose gel electrophoresis. The gray scale of the electrophoresis strip was scanned by an ultraviolet photometry (UVP) gel imaging system. The relative expression of products was represented with TLR4/-actin, TLR2/-actin, MyD88/-actin, and NF-κB/-actin; data were analyzed with an image analysis system.
2.6. Data Analysis
Data were analyzed using software SAS 6.8. Results were means ± SD. Single-factor variance analysis was used to compare the difference between groups, and the q test was used to compare differences between two groups. was considered significant.
3.1. OMT Reduced the Infarction Size of Ischemic Brain Tissue
3.2. OMT Reduced the Water Content of Brain Tissue
With respect to cerebral water content, the following results were noted. There was no difference at 6 hours among the test groups. No change was found at all time points in the sham group. Cerebral water content increased at 24 hours in the saline group and lasted up to 48 hours in the saline group. It was evidently lower in the OMT treatment group, and the difference was significant (Figure 2(d)).
3.3. OMT Reduced the Expression of TLR4, TLR2, MyD88, and NF-κB mRNA
The expression of TLR4, TLR2, MyD88, and NF-κB mRNA in the brain tissue of each group was detected by RT-PCR 24 hours after the operation. The level of TLR4 mRNA expression was higher in the saline group than that in the sham operation group, and was lower in the OMT treatment group than in the saline group. The differences had statistical significance (Figure 3(a)). Expression of NF-κB mRNA 24 hours after the operation was higher in the saline group than in the sham group and was lower in the OMT treatment group than in the saline group. The differences had statistical significance (Figure 3(b)). Results are expressed as means ± SD of each group ( and compared with Sham (Figures 3(c) and 3(d))).
The level of TLR2 mRNA expression was higher in the saline group than that in the sham operation group and was lower in the OMT treatment group than in the saline group. The differences had statistical significance (Figure 4(a)). Expression of MyD88 mRNA 48 hours after the operation was higher in the saline group than in the sham group and was lower in the OMT treatment group than in the saline group. The differences had statistical significance (Figure 4 part (b)). Results are expressed as means ± SD of each group ( compared with Sham and compared with saline group (Figures 4(c) and 4(d))).
3.4. OMT Reduced the Expression of TLR4, TLR2, MyD88, and NF-κB Protein
Expression of TLR4 protein in cerebral tissue was detected by an immunohistochemical technique at 24 hours after the operation in each group. TLR4 expression in the sham group is shown in Figure 5(a). A high level of TLR4 expression in the saline group was noted (Figure 5(b)). TLR4 expression was lower in the OMT treatment group than in the saline group; the difference had statistical significance. Positive cells were defined as having buffy grains in the cytoplasm (Figure 5(c)). Results are expressed as means ± SD of each group ( and compared with Sham (Figure 5(d))).
Expression of NF-κB protein 24 hours after the operation in each group was noted using an immunohistochemical technique. NF-κB expression in the sham group is shown in Figure 6(a). A high level of NF-κB expression in the saline group was observed (Figure 6(b)). NF-κB expression was lower in the OMT group than in the saline group, and the difference had statistical significance. Positive cells were defined as having buffy grains in the nucleus and cytoplasm (Figure 6(c)). Results are expressed as means ± SD of each group ( and compared with Sham (Figure 6(d))).
Expression of TLR2 protein 24 hours after the operation in each group was noted using an immunohistochemical technique. TLR2 expression in the sham group is shown in Figure 7(a). A high level of TLR2 expression in the saline group was observed (Figure 7(b)). TLR2 expression was lower in the OMT group than in the saline group, and the difference had statistical significance. Positive cells were defined as having buffy grains in the cytoplasm (Figure 7(c)). Results are expressed as means ± SD of each group ( compared with Sham and compared with saline group (Figure 7(d))).
Expression of MyD88 protein 24 hours after the operation in each group was noted using an immunohistochemical technique. MyD88 expression in the sham group is shown in Figure 8(a). A high level of MyD88 expression in the saline group was observed (Figure 8(b)). MyD88 expression was lower in the OMT group than in the saline group, and the difference had statistical significance. Positive cells were defined as having buffy grains in the cytoplasm (Figure 8(c)). Results are expressed as means ± SD of each group ( compared with Sham and compared with saline group (Figure 8(d))).
The antiinflammatory and antioxidative effects of OMT (as well as its roles in immunological regulation) have attracted attention over the past few years [13, 14]. It has been confirmed that OMT can act on nonspecific inflammatory reactions . OMT exerts its antiinflammatory effect without dependence of the pituitary-adrenal system: it acts directly on inflammatory cells . OMT is a two-way immunoregulant. That is, it can stimulate the proliferation of lymphocytes at low concentrations, and yet inhibit this proliferation at high concentrations.
Cerebral infarction can be observed in multiple pathological processes  and can be affected by multiple factors. In general, it is believed that cerebral infarction is a typical noninfective lesion, and that its pathophysiological mechanism involves the production of oxygen free radicals and release of inflammatory mediators. TLRs are thought to have important effects on nonbiological inflammatory lesions [1, 17].
TLRs are type-I transmembrane receptors. Their extracellular domain is a pathogen-associated molecular pattern (PAMP). Their intracellular part is a structural domain named Toll/IL-1R (TIR), which can conduct stimulating signals. At least 11 TLRs (TLR1–TLR11) have been identified. TLR4 and TLR2 have been confirmed to participate in the inflammatory reaction, and to promote the maturation and differentiation of immune cells. Various TLRs are expressed in human and murine brains [18, 19]. TLR4 is extensively expressed in the periventricular plexus, microglial cells and astrocytes. TLR4 mRNA is also observed in intracerebral vascular smooth muscle cells and epithelia. TLR2 has been described to express in astrocytes, microglia, endothelial cells, ependymal cells, as well as neurons. Many PAMPs can activate TLR4, including peptidoglycan (PGN), Lipoteichoic acid (LTA), lipoprotein, and oxidative stress (i.e., oxygen free radicals). Potential ligands for TLR2 activation are some endogenous “danger molecules” like high mobility group box protein 1 (Hmgb1) or heat shock protein 70 (HSP70) [20, 21]. Activated TLR4 and TLR2 then transfer signals to NF-κB through MyD88-dependent and independent pathways and induce activation of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-) and interleukins (ILs). TLR family members recognize not only exogenous microorganisms but also endogenous harmful substances . For example, they are involved in the responses to necrotized cells, heat-shock protein, and the degradation products of the extracellular matrix. It was recently indicated that TLR4 and TLR2 have critical effects in injuries to the central nervous system [23–25] and that the microglial cell is the main mediator of such injuries. As an inflammatory transmembrane receptor, the role of TLRs has become a controversial issue in the field of infective diseases. There are many studies on the effects of TLR4 in nonbiological inflammatory injuries (e.g., ischemia of the myocardium, liver, and brain), but there are few reports on ischemic nonbiological infective injury. After cerebral infarction, it has been confirmed that the infective injury around ischemic tissue becomes the direct cause of cerebral edema  but does infective injury after cerebral infarction correlate to TLR4 and TLR2 levels?
We calculated the water content of brain tissue and the infarction size (as determined by TTC stain) to evaluate the influence of OMT on the expression of TLR4, TLR2, MyD88 and NF-κB in focal cerebral infarction in rats. Expression of TLR4, TLR2, MyD88, and NF-κB mRNA and protein in test groups was detected by RT-PCR and immunohistochemistry, respectively. OMT could reduce water content and reduce the infarction area of ischemic brain tissue. It could also weaken the expression of TLR4, TLR2, MyD88, and NF-κB mRNA and protein. We hypothesized that after endogenous activators were identified by TLR4 or TLR2, the signal transduction pathway was switched on. This led to recruitment of MyD88, activation of NF-κB and the subsequent release of proinflammatory cytokines, resulting in tissue injury. By decreasing the expression of TLR4 and TLR2 gene and protein, OMT can reduce the expression of MyD88 and NF-κB gene and protein. This can inhibit inflammatory injury, weaken cerebral edema, and provide neuroprotection against subsequent cerebral ischemic injury. How TLR4, TLR2, and a serial of following inflammatory factors (such as MyD88 and NF-κB) regulate the immune system require further research. Our study showed that administration of 120 mg/kg OMT was sufficient to provide significant neuroprotection against neurological injury induced by MCAO. We supported this finding by both histological and neurological data: a reduction in the brain infarct volume. These results showed that OMT had beneficial effects for ischemia. However, the potential mechanisms underlying the neuroprotection of OMT are not yet known. Our study showed that OMT may ameliorate the inflammation through reducing the expression of TLR4, TLR2, MyD88, and NF-κB.
In conclusion, our study has confirmed that OMT protected the brain from damage caused by MCAO; this effect may be through downregulating the expression of TLR4, TLR2, MyD88, and NF-κB. The elevated expression of TLR4, TLR2, MyD88, and NF-κB is thought to be consistent with ischemia evoked neuron injury and death through inflammatory mechanism. TLR4, TLR2, MyD88, and NF-κB pathway may be one of the strategic targets for cerebral ischemic therapies and OMT maybe a novel, effective therapeutic drug for the treatment of ischemic brain injury.
Hongguang Fan and Litao Li are co-first authors.
- X. Zhang, H. Li, S. Hu et al., “Brain edema after intracerebral hemorrhage in rats: the role of inflammation,” Neurology India, vol. 54, no. 4, pp. 402–407, 2006.
- C. Li, T. Ha, J. Kelley et al., “Modulating Toll-like receptor mediated signaling by --D-glucan rapidly induces cardioprotection,” Cardiovascular Research, vol. 61, no. 3, pp. 538–547, 2004.
- S. Akira, S. Uematsu, and O. Takeuchi, “Pathogen recognition and innate immunity,” Cell, vol. 124, no. 4, pp. 783–801, 2006.
- H. Fan and J. A. Cook, “Molecular mechanisms of endotoxin tolerance,” Journal of Endotoxin Research, vol. 10, no. 2, pp. 71–84, 2004.
- N. S. Soysa and N. Alles, “NF-B functions in osteoclasts,” Biochemical and Biophysical Research Communications, vol. 378, no. 1, pp. 1–5, 2009.
- T. Kawai and S. Akira, “TLR signaling,” Seminars in Immunology, vol. 19, no. 1, pp. 24–32, 2007.
- C. W. Wieland, S. Florquin, N. A. Maris et al., “The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable Haemophilus influenzae from the mouse lung,” Journal of Immunology, vol. 175, no. 9, pp. 6042–6049, 2005.
- N. Tamassia, V. Le Moigne, F. Calzetti et al., “The MyD88-independent pathway is not mobilized in human neutrophils stimulated via TLR4,” Journal of Immunology, vol. 178, no. 11, pp. 7344–7356, 2007.
- C.-X. Cao, Q.-W. Yang, F.-L. Lv, J. Cui, H.-B. Fu, and J.-Z. Wang, “Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice,” Biochemical and Biophysical Research Communications, vol. 353, no. 2, pp. 509–514, 2007.
- L.-G. Lu, M.-D. Zeng, Y.-M. Mao et al., “Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial,” World Journal of Gastroenterology, vol. 9, no. 11, pp. 2480–2483, 2003.
- E. Z. Longa, P. R. Weinstein, S. Carlson, and R. Cummins, “Reversible middle cerebral artery occlusion without craniectomy in rats,” Stroke, vol. 20, no. 1, pp. 84–91, 1989.
- R. J. Laing, J. Jakubowski, and R. W. Laing, “Middle cerebral artery occlusion without craniectomy in rats: which method works best?” Stroke, vol. 24, no. 2, pp. 294–297, 1993.
- Y. Liu, X.-J. Zhang, C.-H. Yang, and H.-G. Fan, “Oxymatrine protects rat brains against permanent focal ischemia and downregulates NF-B expression,” Brain Research, vol. 1268, pp. 174–180, 2009.
- S. Hong-Li, L. Lei, S. Lei et al., “Cardioprotective effects and underlying mechanisms of oxymatrine against ischemic myocardial injuries of rats,” Phytotherapy Research, vol. 22, no. 7, pp. 985–989, 2008.
- F. Liu, J. Liu, X. Chen, W.-W. Lv, and J.-Z. Zheng, “Effect of oxymatrine on inflammation and its mechanism,” Journal of Jilin University. Medicine Edition, vol. 31, no. 5, pp. 728–730, 2005.
- G. K. Rajanikant, D. Zemke, M.-C. Senut et al., “Carnosine is neuroprotective against permanent focal cerebral ischemia in mice,” Stroke, vol. 38, no. 11, pp. 3023–3031, 2007.
- B. Schnabl, K. Brandl, M. Fink et al., “A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells,” Biochemical and Biophysical Research Communications, vol. 375, no. 2, pp. 210–214, 2008.
- M. Bsibsi, R. Ravid, D. Gveric, and J. M. Van Noort, “Broad expression of Toll-like receptors in the human central nervous system,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 11, pp. 1013–1021, 2002.
- T. Kielian, “Toll-like receptors in central nervous system glial inflammation and homeostasis,” Journal of Neuroscience Research, vol. 83, no. 5, pp. 711–730, 2006.
- J. R. Klune, R. Dhupar, J. Cardinal, T. R. Billiar, and A. Tsung, “HMGB1: endogenous danger signaling,” Molecular Medicine, vol. 14, no. 7-8, pp. 476–484, 2008.
- J. S. Park, F. Gamboni-Robertson, Q. He et al., “High mobility group box 1 protein interacts with multiple Toll-like receptors,” American Journal of Physiology, vol. 290, no. 3, pp. C917–C924, 2006.
- A. A. Beg, “Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses,” Trends in Immunology, vol. 23, no. 11, pp. 509–512, 2002.
- N. Laflamme, H. Echchannaoui, R. Landmann, and S. Rivest, “Cooperation between Toll-like receptor 2 and 4 in the brain of mice challenged with cell wall components derived from gram-negative and gram-positive bacteria,” European Journal of Immunology, vol. 33, no. 4, pp. 1127–1138, 2003.
- S. Lehnardt, S. Lehmann, D. Kaul et al., “Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia,” Journal of Neuroimmunology, vol. 190, no. 1-2, pp. 28–33, 2007.
- G. Ziegler, D. Harhausen, C. Schepers et al., “TLR2 has a detrimental role in mouse transient focal cerebral ischemia,” Biochemical and Biophysical Research Communications, vol. 359, no. 3, pp. 574–579, 2007.
Copyright © 2009 Hongguang Fan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.